Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» aducanumab
aducanumab
Beleaguered Biogen faces the music as a chorus of critics push for a transformative approach to M&A
Endpoints
Tue, 05/21/19 - 09:30 am
Biogen
M&A
aducanumab
Credit Suisse
Alzheimer’s R&D projects sidelined as Biogen’s aducanumab shock shakes researchers to the core of their beliefs
Endpoints
Tue, 05/14/19 - 09:56 am
Alzheimer's disease
drug development
aducanumab
Biogen
Eisai
BAN2401
Merck
Eli Lilly
AstraZeneca
Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs
BioSpace
Sun, 05/5/19 - 10:36 am
Eisai
Biogen
Alzheimer's disease
R&D
aducanumab
BAN2401
After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug
NPR
Sat, 05/4/19 - 02:35 pm
Alzheimer's disease
R&D
drug development
beta amyloid
Biogen
Eisai
aducanumab
Biogen cans plan to test aducanumab in Alzheimer's prevention
Fierce Biotech
Wed, 04/24/19 - 12:00 pm
Biogen
Alzheimer's disease
aducanumab
cilnical trials
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Sat, 03/30/19 - 12:44 pm
Alzheimer's disease
Biogen
aducanumab
Otsuka
Axsome Therapeutics
Amgen
Novartis
Avanir
AVP-786
AXS-05
AMG520
Where can Biogen turn after mammoth Alzheimer's blow? The M&A table, analysts say
Fierce Pharma
Thu, 03/21/19 - 12:28 pm
Biogen
Alzheimer's disease
aducanumab
M&A
Biogen halts Alzheimer's drug trials in 'transformative' failure for the biotech
BioPharma Dive
Thu, 03/21/19 - 09:56 am
Biogen
Eisai
Alzheimer's disease
clinical trials
aducanumab
All Eyes on Biogen as Roche Alzheimer’s Drug Flunks Final Test
Xconomy
Wed, 01/30/19 - 11:56 am
Roche
Alzheimer's disease
clinical trials
AC Immune
crenezumab
Biogen
aducanumab
Spinraza sales lift Biogen revenues
BioCentury
Tue, 01/29/19 - 11:15 pm
Biogen
earnings
aducanumab
Alzheimer's disease
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
Sun, 01/6/19 - 02:09 pm
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
Biogen and Eisai Report Phase Ib Extension Data for Alzheimer’s Trial
BioSpace
Tue, 08/28/18 - 07:54 pm
Biogen
Eisai
aducanumab
clinical trials
Alzheimer's disease
5 Experimental New Drugs That Could Be Worth $47 Billion
Motley Fool
Wed, 06/20/18 - 09:26 am
GSK2857916
GSK
brolucizumab
Novartis
aducanumab
Biogen
upadacatinib
AbbVie
VX-659 + tezacaftor + ivacaftor
Vertex Pharmaceuticals
Biogen Pays $50 million to Reduce Future Royalty Payments on Alzheimer’s Drug Aducanumab
CP Wire
Tue, 05/1/18 - 09:48 am
Biogen
Alzheimer's disease
aducanumab
Neurimmune
Biogen Pays $50 million to Reduce Future Royalty Payments on Alzheimer’s Drug Aducanumab
Tue, 05/1/18 - 09:20 am
Biogen
Alzheimer's disease
aducanumab
Biogen’s key Alzheimer’s disease drug is facing potential signs of trouble
Marketwatch
Sun, 02/18/18 - 10:12 am
Biogen
Alzheimer's disease
aducanumab
Biogen tweaks Alzheimer’s phase 3, sparking stock slide
Fierce Biotech
Thu, 02/15/18 - 09:39 am
Biogen
Alzheimer's disease
clinical trials
aducanumab
Biogen Inc. Caps Off a Solid 2017, Waits on Aducanumab
Motley Fool
Mon, 01/29/18 - 11:56 pm
Biogen
aducanumab
earnings
Eisai shows confidence in Biogen's Alzheimer's drug
Biopharma Dive
Mon, 10/23/17 - 09:49 pm
Eisai
Biogen
Alzheimer's disease
aducanumab
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Motley Fool
Sat, 09/16/17 - 12:01 pm
AbbVie
Humira
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
Biogen
aducanumab
Pages
« first
‹ previous
1
2
3
4
5
6
7
next ›
last »